Clinical TrialsDuring the quarter, Acasti announced positive results for its randomized, open-label, dose ranging, multi-centre ("COLT") trial, designed to evaluate the safety and efficacy of different daily doses of CaPre ® on patients with mild to severe hypertriglyceridemia. CaPre ® was found to be safe and effective with significant mean triglyceride reductions above 20% after 8 weeks of treatment with both daily doses of 4.0 grams and 2.0 grams. No serious events were reported indicating that CaPre ® is safe and tolerable at all doses tested. The efficacy of CaPre ® at all doses and increased effect with dose escalation suggests that CaPre ® may be titratable, allowing physicians to adjust dosage in order to better manage patients' medical needs. Going forward, the Corporation plans to release full COLT trial results at an international scientific forum.
Acasti Announces Second Quarter Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts